Alimera Sciences(ALIM) - 2024 Q2 - Quarterly Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports Second Quarter 2024 Results ● Net Revenue up 54% to $27 Million vs. Q2 2023 ● Global End User Demand Up 6% vs. Q2 2023 ● Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals Inc. ATLANTA, August 6, 2024 -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longe ...